In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2554-2563

  Walkty, A ^a,b,c   Adam, H ^b,c   Baxter, M ^c   Denisuik, A ^c   Lagace Wiens P ^b,c   Karlowsky, J A ^b,c   Hoban, D J ^b,c   Zhanel, G G ^a,c  

^a HEALTH SCIENCES CENTRE   (Canada)

^b Diagnostic Services of Manitoba Inc   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PLAZOMICIN; TIGECYCLINE; TOBRAMYCIN; 6'-(HYDROXYLETHYL)-1-(HABA)-SISOMICIN; ANTIINFECTIVE AGENT; SISOMICIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; ENTEROBACTER AEROGENES; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS EPIDERMIDIS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; SISOMICIN; STAPHYLOCOCCUS AUREUS;

EID: 84898640237     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02744-13     Document Type: Article

References (28)

1. Denisuik AJ, Lagacé-Wiens PR, Pitout JD, Mulvey MR, Simner PJ, Tailor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG, Canadian Antimicrobial Resistance Alliance. 2013. Molecular epidemiology of extended-spectrum- lactamase-,AmpC-lactamase-And carbapenemaseproducing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J. Antimicrob. Chemother. 68(Suppl 1):i57-i65. http://dx.doi.org/10.1093/jac/dkt027.
2. Zilberberg MD, Shorr AF. 2013. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009. J. Hosp. Med. 8:559-563. http://dx.doi.org/10.1002/jhm.2080.
3. Zilberberg MD, Shorr AF. 2013. Secular trends in Gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect. Control Hosp. Epidemiol. 34:940-946. http://dx.doi.org/10.1086/671740.
4. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JL, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. 2013. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect. Dis. 13:785-796. http://dx.doi.org/10. 1016/S1473-3099(13)70190-7.
5. Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. 2013. Predictors of mortality in patients with infections due to multi-drug resistant gram negative bacteria: the study, the patient, the bug or the drug? J. Infect. 66:401-414. http://dx.doi.org/10.1016/j.jinf.2012.10.028.
6. Schwaber MJ, Carmeli Y. 2007. Mortality and delay in effective therapy associated with extended-spectrum-lactamase production in Enterobacteriaceae bacteremia: a systematic review and meta-Analysis. J. Antimicrob. Chemother. 60:913-920. http://dx.doi.org/10.1093/jac/dkm318.
7. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. 2009. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase- producing K. pneumoniae. Infect. Control Hosp. Epidemiol. 30: 1180-1185. http://dx.doi.org/10.1086/648451.
8. Mouloudi E, Protonotariou E, Zagorianou A, Iosifidis E, Karapanagiotou A, Giasnetsova T, Tsioka A, Roilides E, Sofianou D, Gritsi-Gerogianni N. 2010. Bloodstream infections caused by metallo-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcome. Infect. Control Hosp. Epidemiol. 31:1250-1256. http://dx.doi.org/10.1086/657135.
9. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. 2010. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob. Agents Chemother. 54:3717-3722. http://dx.doi.org/10.1128/AAC.00207- 10.
10. Boucher HW, Talbot GH, Benjamin DK, Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D, Infectious Diseases Society of America. 2013. 10 '20 progress-development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin. Infect. Dis. 56:1685-1694. http://dx.doi.org/10.1093/cid/cit152.
11. Poulikakos P, Falagas ME. 2013. Aminoglycoside therapy in infectious diseases. Expert Opin. Pharmacother. 14:1585-1597. http://dx.doi.org/10.1517/ 14656566.2013.806486.
12. Doi Y, Yoshichika A. 2007. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin. Infect. Dis. 45:88-94. http://dx.doi.org/10.1086/518605.
13. Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2012. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev. Anti Infect. Ther. 10: 459-473. http://dx.doi.org/10.1586/eri.12.25.
14. Miller GH, Sabatelli FJ, Hare RS, Glupczynski Y, Mackey P, Shlaes D, Shimizu K, Shaw KJ. 1997. The most frequent aminoglycoside resistance mechanisms-changes with time and geographic area: a reflection of aminoglycoside usage patterns? Clin. Infect. Dis. 24(Suppl 1):S46-S62. http://dx.doi.org/10. 1093/clinids/24.Supplement-1.S46.
15. Hirsch EB, Tam VH. 2010. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrugresistant infection. J. Antimicrob. Chemother. 65:1119-1125. http://dx.doi.org/10.1093/ jac/dkq108.
16. Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, Lopez S, Gomez M, Wlasichuk KB, Diokno R, Miller GH, Moser HE. 2010. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob. Agents Chemother. 54:4636-4642. http://dx.doi.org/10.1128/ AAC.00572-10.
17. Landman D, Babu E, Shah N, Kelly P, Bäcker M, Bratu S, Quale J. 2010. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J. Antimicrob. Chemother. 65:2123-2127. http://dx.doi.org/10.1093/jac/dkq278.
18. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
19. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-7th ed. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
20. Galani I, Souli M, Daikos GL, Chrysouli Z, Poulakou G, Psichogiou M, Panagea T, Argyropoulou A, Stefanou I, Plakias G, Giamarellou H, Petrikkos G. 2012. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J. Chemother. 24:191-194. http://dx.doi.org/10.1179/1973947812Y. 0000000015.
21. Endimiani A, Hujer KM, Hujer AM, Armstrong ES, Choudhary Y, Aggen JB, Bonomo RA. 2009. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother. 53:4504-4507. http://dx.doi.org/10.1128/AAC.00556-09.
22. Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. 2011. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother. 66:48-53. http://dx.doi.org/10.1093/jac/dkq408.
23. Georgescu C, Martin DA, Bratu S, Quale J, Landman D. 2009. Activity of ACHN-490, a novel neoglycoside antibiotic, against contemporary Gram-negative clinical isolates from Brooklyn, NY hospitals, abstr F1-842. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
24. Biedenbach DJ, Jones RN, Armstrong ES, Aggen JB, Miller GH. 2009. Activity of ACHN-490 against complicated urinary tract infection (cUTI) pathogens from the United States and Europe, abstr F1-843. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
25. Cass RT, Brooks CD, Havrilla NA, Tack KJ, Borin MT, Young D, Bruss JB. 2011. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob. Agents Chemother. 55:5874-5880. http://dx.doi.org/10.1128/AAC.00624-11.
26. Landman D, Kelly P, Bäcker M, Babu E, Shah N, Bratu S, Quale J. 2011. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J. Antimicrob. Chemother. 66:332-334. http://dx.doi.org/10.1093/jac/dkq459.
27. Riddle V, Cebrik D, Armstrong E, Cass R, Clobes T, Hillan K. 2012. Plazomicin safety and efficacy in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP), abstr L2-2118a. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
28. Tenover FC, Tickler I, Armstrong ES, Kubo A, Lopez S, Persing DH, Miller GH.2011. Activity ofACHN-490against methicillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals. Int. J. Antimicrob. Agents. 38:352-354. http://dx.doi.org/10.1016/j.ijantimicag.2011.05.016.